Molecular mechanisms of membrane impermeability in clinical isolates of Enterobacteriaceae exposed to imipenem selective pressure

International Journal of Antimicrobial Agents

Volumn 48, Issue 1, 2016, Pages 78-85

  Pavez, Monica ^a,b   Vieira, Camila ^a   de Araujo, Maria Rita ^c   Cerda, Alvaro ^a,b   de Almeida, Lara Mendes ^a   Lincopan, Nilton ^a   Mamizuka, Elsa Masae ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSIDAD DE LA FRONTERA   (Chile)

^c HOSPITAL BENEFICÊNCIA PORTUGUESA DE SÃO PAULO   (Brazil)

Author keywords

Carbapenem resistance; Enterobacteriaceae; Imipenem selective pressure; Membrane impermeability

Indexed keywords

BETA LACTAMASE AMPC; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; MEROPENEM; MESSENGER RNA; POLYMYXIN B; TETRACYCLINE; TIGECYCLINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR MARA; TRANSCRIPTION FACTOR OMPR; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ACRA GENE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL OUTER MEMBRANE; CONTROLLED STUDY; ENTEROBACTERIACEAE; GENE EXPRESSION; MEMBRANE PERMEABILITY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; OMP35 GENE; OMP36 GENE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANTIBIOTIC RESISTANCE; CELL MEMBRANE; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETIC SELECTION; HUMAN; MICROBIAL SENSITIVITY TEST; PERMEABILITY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

ANTI-BACTERIAL AGENTS; CELL MEMBRANE; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENTEROBACTERIACEAE; GENE EXPRESSION PROFILING; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; PERMEABILITY; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SELECTION, GENETIC;

EID: 84975105900     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.04.016     Document Type: Article

References (37)

1. [1] Orsi, G.B., García-Fernandez, A., Giordano, A., Venditti, C., Bencardino, A., Gianfreda, R., et al. Risk factors and clinical significance of ertapenem-resistant Klebsiella pneumoniae in hospitalised patients. J Hosp Infect 78 (2011), 54–58.
2. [2] Patel, N., Harrington, S., Dihmess, A., Woo, B., Masoud, R., Martis, P., et al. Clinical epidemiology of carbapenem-intermediate or -resistant Enterobacteriaceae. J Antimicrob Chemother 66 (2011), 1600–1608.
3. [3] Bornet, C., Davin-Regli, A., Bosi, C., Pages, J.M., Bollet, C., Imipenem resistance of Enterobacter aerogenes mediated by outer membrane permeability. J Clin Microbiol 38 (2000), 1048–1052.
4. [4] Nikaido, H., Pagès, J.M., Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiol Rev 36 (2012), 340–363.
5. [5] Martínez-Martínez, L., Hernández-Allés, S., Albertí, S., Tomás, J.M., Benedi, V.J., Jacoby, G.A., In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum-cephalosporins. Antimicrob Agents Chemother 40 (1996), 342–348.
6. [6] Poirel, L., Heritier, C., Spicq, C., Nordmann, P., In vivo acquisition of high-level resistance to imipenem in Escherichia coli. J Clin Microbiol 42 (2004), 3831–3833.
7. [7] Pavez, M., Neves, P., Dropa, M., Matté, M.H., Grinbaum, R.S., Elmor de Araújo, M.R., et al. Emergence of carbapenem-resistant Escherichia coli producing CMY-2-type AmpC β-lactamase in Brazil. J Med Microbiol 57 (2008), 1590–1592.
8. [8] Oteo, J., Delgado-Iribarren, A., Vega, D., Bautista, V., Rodríguez, M.C., Velasco, M., et al. Emergence of imipenem resistance in clinical Escherichia coli during therapy. Int J Antimicrob Agents 32 (2008), 534–537.
9. [9] Song, W., Suh, B., Choi, J.Y., Jeong, S.H., Jeon, E.H., Lee, Y.K., et al. In vivo selection of carbapenem-resistant Klebsiella pneumoniae by OmpK36 loss during meropenem treatment. Diagn Microbiol Infect Dis 65 (2009), 447–449.
10. [10] Findlay, J., Hamouda, A., Dancer, S.J., Amyes, S.G., Rapid acquisition of decreased carbapenem susceptibility in a strain of Klebsiella pneumoniae arising during meropenem therapy. Clin Microbiol Infect 18 (2012), 140–146.
11. [11] Doumith, M., Ellington, M.J., Livermore, D.M., Woodford, N., Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J Antimicrob Chemother 63 (2009), 659–667.
12. [12] Hasdemir, U.O., Chevalier, J., Nordmann, P., Pagès, J.M., Detection and prevalence of active drug efflux mechanism in various multidrug-resistant Klebsiella pneumoniae strains from Turkey. J Clin Microbiol 42 (2004), 2701–2706.
13. [13] Bornet, C., Chollet, R., Malláa, M., Chevalier, J., Davin-Regli, A., Pagès, J.M., et al. Imipenem and expression of multidrug efflux pump in Enterobacter aerogenes. Biochem Biophys Res Commun 301 (2003), 985–990.
14. [14] Yang, F.C., Yan, J.J., Hung, K.H., Wu, J.J., Characterization of ertapenem-resistant Enterobacter cloacae in a Taiwanese university hospital. J Clin Microbiol 50 (2012), 223–226.
15. [15] Bialek-Davenet, S., Marcon, E., Leflon-Guibout, V., Lavigne, J.P., Bert, F., Moreau, R., et al. In vitro selection of ramR and soxR mutants overexpressing efflux systems by fluoroquinolones as well as cefoxitin in Klebsiella pneumoniae. Antimicrob Agents Chemother 55 (2011), 2795–2802.
16. [16] Martínez-Martínez, L., Extended-spectrum β-lactamases and the permeability barrier. Clin Microbiol Infect 14:Suppl. 1 (2008), 82–89.
17. [17] Arakawa, Y., Shibata, N., Shibayama, K., Kurokawa, H., Yagi, T., Fujiwara, H., et al. Convenient test for screening metallo-β-lactamase-producing Gram-negative bacteria by using thiol compounds. J Clin Microbiol 38 (2000), 40–43.
18. [18] Coudron, P.E., Inhibitor-based methods for detection of plasmid-mediated AmpC β-lactamases in Klebsiella spp., Escherichia coli, and Proteus mirabilis. J Clin Microbiol 43 (2005), 4163–4167.
19. [19] Clinical and Laboratory Standards Institute, Performance standards for antimicrobial disk susceptibility tests, approved standard. 9th ed Document M02-A9, 2012, CLSI, Wayne, PA.
20. [20] Gautom, R.K., Rapid pulsed-field gel electrophoresis protocol for typing of Escherichia coli O157:H7 and other Gram-negative organisms in 1 day. J Clin Microbiol 35 (1997), 2977–2980.
21. [21] Aydin, F., Gümüşsoy, K.S., Atabay, H.I., Iça, T., Abay, S., Prevalence and distribution of Arcobacter species in various sources in Turkey and molecular analysis of isolated strains by ERIC-PCR. J Appl Microbiol 103 (2007), 27–35.
22. [22] Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing: twenty-fourth informational supplement. Document M100-S24, 2014, CLSI, Wayne, PA.
23. [23] Clinical and Laboratory Standards Institute, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 9th ed Document M07-A9, 2012, CLSI, Wayne, PA.
24. [24] Balsalobre, L.C., Dropa, M., Lincopan, N., Mamizuka, E.M., Matté, G.R., Matté, M.H., Detection of metallo-β-lactamases-encoding genes in environmental isolates of Aeromonas hydrophila and Aeromonas jandaei. Lett Appl Microbiol 49 (2009), 142–145.
25. [25] Gales, A.C., Tognim, M.C., Reis, A.O., Jones, R.N., Sader, H.S., Emergence of an IMP-like metallo-enzyme in an Acinetobacter baumannii clinical strain from a Brazilian teaching hospital. Diagn Microbiol Infect Dis 45 (2003), 77–79.
26. [26] Kvist, M., Hancock, V., Klemm, P., Inactivation of efflux pumps abolishes bacterial biofilm formation. Appl Environ Microbiol 74 (2008), 7376–7382.
27. [27] Hutsul, J.A., Worobec, E., Molecular characterization of a 40 kDa OmpC-like porin from Serratia marcescens. Microbiology 140 (1994), 379–387.
28. [28] Yoshida, T., Qin, L., Egger, L.A., Inouye, M., Transcription regulation of ompF and ompC by a single transcription factor, OmpR. J Biol Chem 281 (2006), 17114–17123.
29. [29] Girlich, D., Poirel, L., Nordmann, P., CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother 53 (2009), 832–834.
30. [30] Tsai, Y.K., Liou, C.H., Fung, C.P., Lin, J.C., Siu, L.K., Single or in combination antimicrobial resistance mechanisms of Klebsiella pneumoniae contribute to varied susceptibility to different carbapenems. PLoS ONE, 8, 2013, e79640.
31. [31] Chia, J.H., Su, L.H., Lee, M.H., Kuo, A.J., Shih, N.Y., Siu, L.K., et al. Development of high-level carbapenem resistance in Klebsiella pneumoniae among patients with prolonged hospitalization and carbapenem exposure. Microb Drug Resist 16 (2010), 317–325.
32. [32] Lavigne, J.P., Sotto, A., Nicolas-Chanoine, M.H., Bouziges, N., Pagès, J.M., Davin-Regli, A., An adaptive response of Enterobacter aerogenes to imipenem: regulation of porin balance in clinical isolates. Int J Antimicrob Agents 41 (2013), 130–136.
33. [33] Urban, J.H., Vogel, J., Translational control and target recognition by Escherichia coli small RNAs in vivo. Nucleic Acids Res 35 (2007), 1018–1037.
34. [34] Piddock, L.J., Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev 19 (2006), 382–402.
35. [35] Begic, S., Worobec, E.A., The role of the Serratia marcescens SdeAB multidrug efflux pump and TolC homologue in fluoroquinolone resistance studied via gene-knockout mutagenesis. Microbiology 154 (2008), 454–461.
36. [36] Rosenblum, R., Khan, E., Gonzalez, G., Hasan, R., Schneiders, T., Genetic regulation of the ramA locus and its expression in clinical isolates of Klebsiella pneumoniae. Int J Antimicrob Agents 38 (2011), 39–45.
37. [37] Adler, M., Anjum, M., Andersson, D.I., Sandegren, L., Combinations of mutations in envZ, ftsI, mrdA, acrB and acrR can cause high-level carbapenem resistance in Escherichia coli. J Antimicrob Chemother 71 (2016), 1188–1198.